BIVIW
BioVie Inc Warrant (BIVIW)
NASDAQ • $0.28-5.67%
- Symbol
- BIVIW
- Exchange
- NASDAQ
- Sector
- Industry
- Price
- $0.28
- Daily Change
- -5.67%
- Market Cap
- N/A
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $0.30
- 52W Low
- $0.27
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.72
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Company websiteResearch BIVIW on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.